Credit: BioLineRx. Aphexda is expected to be available in September 2023. The Food and Drug Administration (FDA) has approved Aphexda ™ (motixafortide) in combination with filgrastim (granulocyte ...
CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and appeared safe in patients with recurrent glioblastoma (GBM) in a phase I study ...
Please provide your email address to receive an email when new articles are posted on . Patients receiving injections of autologous adipose-derived stem cells or adipose-derived stromal vascular ...
The combination therapy is the first FDA approved for the mobilization of hematopoietic stem cells prior to autologous transplantation in patients with multiple myeloma. The FDA approved motixafortide ...
CNSide® may catalyze LM treatment initiation, allow physicians to adapt treatment with real time shifts in tumor biology, and enable personalized cancer therapy HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback